Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

Summary

The purpose of this study is to describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received either zoledronic acid (Zometa®) or denosumab.

Timeline

Start

2009-07

Primary completion

2012-02

Completion

2012-04

Drugs

Indications